Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 5 records in total 5
    records per page

    Safety measures for COVID-19 do not compromise the outcomes of patients undergoing primary percutaneous coronary intervention: A single center study

    Authors: Xiaonan Guan; Jianjun Zhang; Yanbing Li; Ning Ma

    doi:10.21203/ Date: 2020-10-06 Source: ResearchSquare

    Coronavirus disease MESHD 2019 (COVID-19) is a global pandemic impacting nearly 170 countries/regions and millions of patients worldwide. Patients with acute myocardial infarction MESHD myocardial infarction HP ( AMI MESHD) still need to be treated at percutaneous coronary intervention (PCI) centers with relevant safety measures. This study was conducted to assess the therapeutic outcomes of PCI performed under the safety measures and normal conditions. AMI MESHD patients undergoing PCI between January 24 to April 30, 2020 were performed under safety measures for COVID-19. Patients received pulmonary computed tomography (CT) and underwent PCI in negative pressure ICU. Cardiac catheterization laboratory (CCL) staff and physicians worked with level Ⅲ personal protection. Demographic and clinical data, such as door-to-balloon (DTB) time, operation time, complications for patients in this period (NCP group) and the same period in 2019 (2019 group) were retrieved and analyzed. NCP and 2019 groups had 37 and 96 patients, respectively. There was no significant difference in age TRANS, gender TRANS, BMI and comorbidity between the two groups. DTB time and operation time were similar between the two groups (60.0 ± 12.39 vs 58.83 ± 12.85 min, p = 0.636; 61.46 ± 9.91 vs 62.55 ± 10.72 min, p = 0.592). Hospital stay time in NCP group was significantly shorter (6.78 ± 2.14 vs 8.85 ± 2.64 days, p < 0.001). The incidences of malignant arrhythmia MESHD arrhythmia HP and Takotsubo Syndrome MESHD in NCP group were higher than 2019 group significantly (16.22% vs 5.21%, p = 0.039; 10.81% vs 1.04% p = 0.008). During hospitalization and 3-month follow-up, the incidence of major adverse cardiovascular events and mortality in the two groups were statistically similar (35.13% vs 14.58%, p = 0.094; 16.22% vs 8.33%, p =0.184). Our analysis showed that safety measures undertaken in this hospital, including screening of COVID-19 infection MESHD and use of personal protection equipment for conducting PCI did not compromise the surgical outcome as compared with PCI under normal condition, although there were slight increases in incidence of malignant arrhythmia MESHD arrhythmia HP and Takotsubo Syndrome MESHD.

    Findings on the relationship between cardiovascular disease MESHD and coronavirus disease MESHD 2019: a systematic review

    Authors: Yuri Henrique da Silva1; José Gildo de Moura Monteiro Júnior; Rosângela Ferreira Frade de Araújo

    doi:10.21203/ Date: 2020-09-28 Source: ResearchSquare

    Coronavirus disease 2019 (COVID-19) presents as the main cause of death MESHD, respiratory and heart failures MESHD, especially in the elderly TRANS, immunosuppressed, and those with cardiovascular comorbidities. Therefore, a better understanding of these findings is needed. A systematic review was carried out looking for articles published between December 2019 and May 2020 on the MEDLINE / PubMed search platform using the following descriptors: (((((((((" cardiovascular disease MESHD") OR ("acute myocardial infarction HP myocardial infarction MESHD")) OR (" coronary artery disease MESHD")) OR ("acute coronary syndrome MESHD")) OR (" atherosclerosis HP atherosclerosis MESHD")) OR (" cardiac insufficiency MESHD")) OR (" pericarditis HP pericarditis MESHD")) OR (" myocarditis HP myocarditis MESHD")) AND ("COVID-19")) OR ("SARS-CoV-2")and considering inclusion and exclusion criteria.40% of patients infected with SARS-CoV-2 had hypertension HP hypertension MESHD or other cardiovascular comorbidities, while 27% presented cardiovascular complications, mainly acute cardiac injury MESHD, arrhythmia HP arrhythmia MESHD and heart failure MESHD. The hypotheses of involvement of an intense inflammatory response, decreased HP immunity and greater expression of ACE2 in the heart, associated with more severe heart conditions, were discussed in this study. The increase in cardiac and inflammatory markers was associated with worse clinical outcomes and risk of death MESHD, confirming the need to evaluate them since admission to the hospital. The 10 articles analyzed presented as a limitation the small number of patients inserted, to the detriment of the pandemic state. We warned about the need for better clinical management of patients with cardiovascular comorbidities MESHD, and the importance of including this group among the first to be immunized, aiming at reducing the number of fatal cases due to infection MESHD. Studies with greater coverage are needed for a better comprehension of the topics discussed here.

    Cardiac Arrhythmias MESHD Arrhythmias HP and COVID-19 – a Meta-analysis of Recent Reports

    Authors: Husam M. I. Salah; Jawahar L. Mehta

    doi:10.21203/ Date: 2020-06-23 Source: ResearchSquare

    Introduction: The 2019 novel coronavirus disease MESHD (COVID-19) is a current pandemic. Cardiovascular manifestations of COVID-19 have been described in many studies; however, no studies have examined the prevalence SERO and characterizations of cardiac arrhythmias MESHD arrhythmias HP among patients with COVID-19 infection MESHD. The aim of this meta-analysis was to examine the prevalence SERO of cardiac arrhythmias MESHD arrhythmias HP among patients with COVID-19 infection MESHD.Method: PubMed, Google Scholar, and ResearchGate databases were searched for relevant articles from inception until June 14, 2020. Inclusion criteria were: 1) Cohort studies or case series studies; 2) Study population included individuals with confirmed COVID-19 infection MESHD; 3) Arrhythmic events were reported in the study. All other studies were excluded. MedCalc software was used to analyze the pooled data. The random-effect model was utilized to obtain the prevalence SERO of arrhythmia HP arrhythmia MESHD among the included patients and its 95% confidence interval. Cohran's Q and I2 index were used for heterogeneity measurements. The main planned outcome was the prevalence SERO of arrhythmia HP arrhythmia MESHD among patients with COVID-19 infection MESHD.Results: Thirteen studies with a total of 2861 patients met our inclusion criteria. The prevalence SERO of arrhythmia HP arrhythmia MESHD among patients with COVID-19 infection MESHD was 8.1% (95% CI [6.10, 10.37]). 82.8% of the patients who had arrhythmia HP arrhythmia MESHD has severe illness (95% CI [70.916, 92.124]).Conclusion: The prevalence SERO of arrhythmias HP arrhythmias MESHD among patients with COVID-19 infection MESHD is 8.1%, which is much higher than in the general population (2.35%). 

    Human iPSC-Derived Cardiomyocytes are Susceptible to SARS-CoV-2 Infection MESHD

    Authors: Arun Sharma; Gustavo Garcia Jr.; Vaithilingaraja Arumugaswami; Clive N Svendsen

    doi:10.1101/2020.04.21.051912 Date: 2020-04-21 Source: bioRxiv

    Coronavirus disease 2019 (COVID-19) is a viral pandemic caused by the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). COVID-19 is predominantly defined by respiratory symptoms, but cardiac complications including arrhythmias HP arrhythmias MESHD, heart failure MESHD, and viral myocarditis HP myocarditis MESHD are also prevalent. Although the systemic ischemic MESHD and inflammatory responses caused by COVID-19 can detrimentally affect cardiac function, the direct impact of SARS-CoV-2 infection MESHD on human cardiomyocytes is not well-understood. We used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as a model system to examine the mechanisms of cardiomyocyte-specific infection by SARS-CoV-2. Microscopy and immunofluorescence demonstrated that SARS-CoV-2 can enter and replicate within hiPSC-CMs, localizing at perinuclear locations within the cytoplasm. Viral cytopathic effect induced hiPSC-CM apoptosis MESHD and cessation of beating after 72 hours of infection MESHD. These studies show that SARS-CoV-2 can infect hiPSC-CMs MESHD in vitro, establishing a model for elucidating the mechanisms of infection MESHD and potentially a cardiac-specific antiviral drug screening platform.

    Clinical features of critically ill MESHD patients with COVID-19 infection MESHD in China

    Authors: Bo Hu; Dawei Wang; Chang Hu; Ming Hu; Fangfang Zhu; Hui Xiang; Beilei Zhao; Xiaoyi Zhang; Kianoush B. Kashani; Zhiyong Peng

    doi:10.21203/ Date: 2020-03-02 Source: ResearchSquare

    Importance: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections MESHD outbreak in China is now a global issue. There is only a limited understanding of the clinical characteristics of patients with SARS-CoV-2 infections MESHD is available.Objective:To describe the characteristics, management strategies, and outcomes of critically ill MESHD patients with SARS-CoV-2 infection MESHD.Design, Setting, and Patients: This is aretrospective, multi-center case series of 50 critically ill MESHD patients with confirmed SARS-CoV-2 infection MESHD who were admitted at Zhongnan Hospital of Wuhan University and Wuhan Pulmonary Hospital in Wuhan, China, from January 8 to February 9, 2020.Exposures:Documented Corona Virus Disease MESHD, 2019 (COVID-19).Main Outcome Measures: Demographic, clinical, laboratory, imaging data were collected along with management strategies, complications and outcomes of enrolled individuals. Results Fifty critically ill MESHD patients with SARS-CoV-2 infections MESHD were enrolled. Their median age TRANS was 62 (range, 29-92) [IQR,49.5-69.0] years, 68% were male TRANS, and 28 (56%) patients had comorbidities, the most common being hypertension HP hypertension MESHD. In this cohort, 20(40%) patients survived ,16(32%) patients died, and the rest remained hospitalized. The invasive mechanical ventilator was used in 36(72%) patients with 15(30%) of them requiring prone positioning, and 17(34%) switched to ECMO. The compliance scores of lungs (Cstat)on the day of ICU admission among survivors were higher than those in non-survivors [42.0(18.0-47.0), vs. 19.5(14.0-24.2), p=0.038].The blood SERO IL-6 levels and neutrophils counts at the first day of ICU admission were significantly higher in non-survivors compared to survivors [123.7(85.3-228.8), vs. 20.2(6.8-67.2) ng/ml, p=0.025 for IL-6, and 20.2(6.8-67.2) vs. 4.01(1.99-7.05) × 10⁹/L, p=0.02 for neutrophils counts].The heart rates, PaCO2, lung injury MESHD scale (LIS), and positive end-expiratory pressure levels were constantly higher for 10 days in non-survivors than those who survived (p<0.05). The frequency of vasopressor uses and neuromuscular blockers was higher in non-survivors from day 1 to day 10 compared to survivors (p<0.05). In the whole cohort, the most common complications were ARDS (97%), shock HP shock MESHD (44%), arrhythmia HP arrhythmia MESHD (38%), acute cardiac injury MESHD (26%), and acute kidney injury HP acute kidney injury MESHD (22%). A secondary bacterial infection MESHD was noted in 17(34%) patients. Univariate analysis indicated that lower lung complianceand higher neutrophil counts at the day of ICU admission were related to higher mortality (p-0.03, and 0.04, respectively)ConclusionWe demonstrated that SARS-CoV-2 infection MESHD-related critical illness predominantly affected old individuals with comorbidities and characterized by severe hypoxemic respiratory failure MESHD respiratory failure HP, often requiring prolonged mechanical ventilation and rescue therapies. Low lung compliance and persistently elevated PaCO2 indicated poor outcomes.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.